

Cipla USA Announces Launch of Pomalidomide Capsules (generic of Pomalyst®) Across All Strengths

Mumbai, India and Warren, New Jersey, USA – September 2026 - Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"), today announced the launch of Pomalidomide Capsules, a generic equivalent of Pomalyst® by Celgene Corporation, a Bristol-Myers Squibb company.

Pomalidomide capsules are a prescription medicine indicated for the treatment of adult patients with multiple myeloma, when taken in combination with dexamethasone, in patients who have received at least two prior therapies, including a type of medicine known as a proteasome inhibitor and lenalidomide, and whose disease has progressed during treatment or within 60 days of completion of the last therapy.

Pomalidomide capsules are also indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART), and for adult patients with HIV-negative KS.

Pomalidomide capsules are available in 1mg, 2mg, 3mg, and 4mg strengths.

Marc Falkin, Chief Executive Officer, Cipla North America, added: *"This launch reinforces Cipla's long-standing commitment to expanding access to high-quality, affordable oncology therapies. As we continue to build a comprehensive portfolio across the treatment continuum, our focus remains on improving patient outcomes, addressing barriers to care, and supporting continuity of treatment, including through co-pay assistance programs for eligible patients."*

The drug will be manufactured at Cipla's approved site offering strong assurance of uninterrupted supply.

According to IQVIA, Pomalidomide Capsules had estimated sales of USD 2.69 billion*.

Cipla is part of the PS-Pomalidomide REMS (Risk Evaluation & Mitigation Strategy) Program, the same program followed by the innovator. This helps ensure patient safety and compliance with FDA requirements.

About Cipla Limited

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 70+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Jun'26). For nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the center of the HIV movement. A responsible

*MAT Jun 2026

corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

investorrelations@cipla.com